Strategy of utilizing in vitro and in vivo ADME tools for lead optimizaton and drug candidate selection

Current Topics in Medicinal Chemistry

Volumn 5, Issue 11, 2005, Pages 1033-1038

  Balani, Suresh K ^a   Miwa, Gerald T ^a   Gan, Liang Shang ^a   Wu, Jing Tao ^a   Lee, Frank W ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

ADME; Discovery assay by stage; Drug drug interactions; High throughput screening; Lead optimization; Transporters

Indexed keywords

1 AMINOBENZOTRIAZOLE; DRUG; DRUG CARRIER; ELACRIDAR; MONOCLONAL ANTIBODY; VERAPAMIL; VERLUKAST;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; DRUG UTILIZATION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; REVIEW; TOXICITY TESTING; TREATMENT FAILURE;

DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; METHODS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 27744584321     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774297038     Document Type: Review

References (20)

1. Reichert, J. M. Trends in development and approval times for new therapeutics in the United States, Nat. Rev. Drug Disc. 2003, 2, 695-702.
2. Sasseville, V. G.; Lane, J. H.; Kadambi, V. J.; Bouchard, P.; Lee, F. W.; Balani, S. K.; Miwa, G. T.; Smith, P. F.; Alden, C. L. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem. Biol. Interac. 2004, 150, 9-25.
3. Balani, S. K, Li, P.; Nguyen, J.; Cardoza, K.; Zeng, H.; Mu, D. X.; Wu, J. T.; Gan, L. S.; Lee, F. W. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in Guinea pigs and mice using serial sampling. Drug Metab. Dispos. 2004, 32, 1092-5.
4. Balani, S. K.; Zhu, T.; Yang, T. J, Liu, Z.; He, B.; Lee, F. W. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab. Dispos. 2002, 30, 1059-62.
5. Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W. D. Pharmacogenetics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Update 2003, 6, 71-84.
6. Lipinski, C. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov Today 2003, 8, 12-16.
7. Andrews, C. W.; Bennett, L.; Yu L. X. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res, 2000, 17, 639-644.
8. Waterbeemd, H. V. D.; Gifford, E. ADMET in silico modeling: Towards prediction paradise? Nat. Rev. Drug Discov. 2003, 2, 192-204.
9. Solon, E. G.; Balani, S. K.; Lee, F. W. Whole-body autoradiography in drug discovery. Curr. Drug Metab. 2002, 3, 451-62.
10. Rudin, M.; Weissledger, R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2, 123-131.
11. Grillo, M. P.; Benet, L. Z. Studies on the Reactivity of Clofibryl-S-Acyl-CoA Thioester with Glutathione in vitro. Drug Metab. Disp. 2002, 30, 55-62.
12. Sandhu, P.; Vogel, J. S.; Rose, M. J.; Ubick, E. A.; Brunner, J. E.; Wallace, M. A.; Adelsberger, J. K.; Baker, M. P, Henderson, P. T.; Pearson, P. G.; Baillie, T. A. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokineties in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. 2004, 32, 1254-9.
13. Lappin, G.; Garner, R. C. Current perspectives in 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem. 2004, 378, 356-364.
14. Li, A. P, In vitro approaches to evaluate ADMET drug properties. Curr. Topics Med. Chem. 2004, 4, 701-707.
15. Davit B.; Reynolds, K.; Yuan, R.; Ajayi, F.; Connor, D.; Fadiran, E,; Gillespie, B.; Sahajwalla, C.; Huang, S.-M.; Lesko, L. J. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling. J. Clin. Pharmacol. 1999, 39, 899-910.
16. Venkatakrishnan, K.; von Moltke, L. L.; Greenblatt, D. J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 2001, 297, 326-37.
17. Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, R. S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31, 815-32.
18. Kennedy, T. Drug Disc. Today 1997, 2, 436.
19. CMR International, Products in the pipeline, CMR01-153R, 2001, 8, 25-34.
20. Tufts Center for the study of drug development. Outlook 2005. www.csdd.tufts.edu.